Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Multiple myeloma is most common in people age 65 and older. The average age of diagnosis is 70, with fewer than 1% of cases diagnosed in people younger than 35.

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

A Cumberland County woman, who, earlier this year, was given months to live, is now thriving due to a newly-approved, cutting ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

"Back in the 1990s, multiple myeloma was a dreaded disease and patients had dismal outcomes," Vishwanath Sathyanarayanan, MD, DM, of Apollo Cancer Centers in Bangalore, India, said in an interview.

An expert discusses how frontline management of transplant-ineligible multiple myeloma has progressed from melphalan-based regimens to modern anti-CD38–based combinations, now including emerging ...